Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Hematology Hepatology Immunology Infectious Disease Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Clinical and Economic Utility of BTK Inhibitors in CLL

home / peer-exchange / clinical-and-economic-utility-of-btk-inhibitors-in-cll

A panel of experts discuss chronic lymphocytic leukemia, focusing on the integration of Bruton tyrosine kinase inhibitors into the treatment landscape, the economic and access considerations of BTK inhibitor therapy, and future directions and ongoing research opportunities in the management of CLL.

A panel of 4 experts on CLL

EP. 1: Recent Trends and Innovations in the Management of CLL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts on the treatment of chronic lymphocytic leukemia discuss recent trends and innovations in the therapeutic landscape.

Watch

A panel of 4 experts on CLL

EP. 2: CLL Treatment Landscape: Overview of BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts provide an overview of BTK inhibitors for the treatment of patients with chronic lymphocytic leukemia.

Watch

A panel of 4 experts on CLL

EP. 3: Evaluating Value of BTK Inhibitors in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts evaluate the value of BTK inhibitors in CLL treatment.

Watch

A panel of 4 experts on CLL

EP. 4: Factors Influencing Choice of Second-Generation BTKi Monotherapy

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Specialists discuss factors influencing the choices of second-generation BTK monotherapy.

Watch

A panel of 4 experts on CLL

EP. 5: Empowering Patients: Key Considerations for BTK Inhibitor Adherence

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A conversation on how to empower patients and the considerations for BTK inhibitor adherence.

Watch

A panel of 4 experts on CLL

EP. 6: Optimizing Therapy Sequencing in CLL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A panel of experts discuss optimizing therapy sequencing in CLL.

Watch

A panel of 4 experts on CLL

EP. 7: Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

Experts discuss leveraging MAICs for decision-making when choosing a CLL BTK inhibitor.

Watch

A panel of 4 experts on CLL

EP. 8: Decision-Making in CLL: The Role of Real-World Evidence

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

A discussion on therapeutic decision-making in CLL and the role of real-world evidence.

Watch

A panel of 4 experts on CLL

EP. 9: Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 5th 2024

A panel of experts discuss combination regimens with BTK inhibitors.

Watch

A panel of 4 experts on CLL

EP. 10: Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 5th 2024

Experts discuss financial challenges of BTK inhibitor therapy.

Watch

A panel of 4 experts on CLL

EP. 11: Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 12th 2024

A panel of experts discuss navigating access challenges in CLL treatment.

Watch

A panel of 4 experts on CLL

EP. 12: The Inflation Reduction Act: Implications for Patient Access in CL

Ryan Haumschild, PharmD, MS, MBA;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 12th 2024

A group of experts discuss implications for patient access in CLL.

Watch

A panel of 4 experts on CLL

EP. 13: Patient Access Advocacy for BTK Inhibitors

Ryan Haumschild, PharmD, MS, MBA, CPEL;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 19th 2024

A panel of specialists discuss patient access advocacy for BTK inhibitors.

Watch

A panel of 4 experts on CLL

EP. 14: Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Ryan Haumschild, PharmD, MS, MBA, CPEL;Roy Beveridge, MD;Brian T. Hill, MD, PhD;Adam S. Kittai, MD

August 19th 2024

Experts discuss future directions of BTK inhibitors.

Watch

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences
AJMC®
All rights reserved.